Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2023 | Percentile | Sector n |
|---|---|---|---|---|
| Elelgrupi | Pharma | 39.1% | 89th pct | 123 |
| Pip Company | Pharma | -10.6% | 10th pct | 123 |
| Sando Pharma | Pharma | -22.9% | 7th pct | 123 |
| Grasse Pharma Georgia | Pharma | — | no FY data | 123 |
| Medimex | Pharma | — | no FY data | 123 |
Percentile is within each company's own sector across the whole FY2023 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2023 | Pip Company | Elelgrupi | Sando Pharma | Grasse Pharma Georgia | Medimex |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 2.2% | 66.9% | 9.8% | — | — |
| EBITDA Margin | -10.6% | 39.1% | -22.9% | — | — |
| EBITDAR | -293 | 697 | -297 | — | — |
| EBITDAR Margin | -9.7% | 41.0% | -22.2% | — | — |
| EBIT Margin | -10.6% | 38.4% | -26.2% | — | — |
| Net Profit Margin | -12.3% | 38.4% | -27.5% | — | — |
| Operating Expense % of Sales | 12.8% | 27.8% | 32.7% | — | — |
| Returns | |||||
| Return on Assets (ROA) | -11.8% | 27.2% | -53.9% | — | — |
| Return on Equity (ROE) | N/A | 48.1% | N/A | — | — |
| ROIC [EBIT / Invested Capital] | N/A | 56.7% | -230.3% | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.0% | 45.8% | — | — |
| Debt-to-Equity | -0.00x | 0.00x | -2.00x | — | — |
| Debt-to-EBITDA | N/A | 0.00x | N/A | — | — |
| Equity-to-Assets | -40.7% | 56.6% | -22.9% | — | — |
| Net Debt | -4 | -207 | 309 | — | — |
| Cash & Equivalents | 4 | 207 | 5 | — | — |
| Total Debt | N/A | N/A | 314 | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.71x | 1.21x | 0.78x | — | — |
| Quick Ratio | 0.71x | 1.21x | 0.78x | — | — |
| Cash Ratio | 0.00x | 0.20x | 0.01x | — | — |
| Total Current Assets | 3,137 | 1,256 | 458 | — | — |
| Total Current Liabilities | 4,412 | 1,039 | 584 | — | — |
| Inventory | N/A | N/A | N/A | — | — |
| Trade Receivables | 2,941 | 795 | N/A | — | — |
| Trade Payables | 4,412 | N/A | 523 | — | — |
| Net Working Capital | -1,275 | 217 | -126 | — | — |
| Net Working Capital % of Revenue | -42.5% | 12.8% | -9.4% | — | — |
| Trade Working Capital | -1,472 | 795 | -523 | — | — |
| Trade Working Capital % of Revenue | -49.0% | 46.8% | -39.0% | — | — |
| Change in Trade Working Capital | N/A | N/A | N/A | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | — | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | — | — |
| Receivables Turnover | 1.02x | 2.14x | N/A | — | — |
| Days Sales Outstanding (DSO) | 357.4 | 170.8 | N/A | — | — |
| Payables Turnover | 0.67x | N/A | 2.31x | — | — |
| Days Payable Outstanding (DPO) | 548.5 | N/A | 157.8 | — | — |
| Cash Conversion Cycle | -191.1 days | 170.8 days | -157.8 days | — | — |
| Asset Turnover | 0.96x | 0.71x | 1.96x | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | 2,779 | N/A | — | — |
| Free Cash Flow (OCF − Capex proxy) | N/A | 85 | N/A | — | — |
| Cash Conversion (OCF / EBITDA) | N/A | 418.3% | N/A | — | — |
| Dividends Declared | N/A | N/A | N/A | — | — |
| Dividend Payout Ratio | N/A | N/A | N/A | — | — |